Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate Lucid-MS for multiple sclerosis while simultaneously pursuing commercial opportunities with its unbuzzd product, according to Executive Co-Chairman and Co-Founder Anthony Durkacz in a recent BioMedWire Podcast. The company has filed an investigational new drug application for a Phase 2 clinical trial of Lucid-MS, which could mark the first administration of the candidate to human MS patients. Lucid-MS aims to address mobility damage associated with MS, a neurodegenerative disease affecting millions worldwide.
Durkacz underscored Quantum BioPharma’s strategy of combining clinical-stage pharmaceutical development with commercial ventures. The company’s unbuzzd product, designed to accelerate alcohol metabolism, is already commercially available through a spin-out company, Unbuzzd Wellness Inc. (UWI). Quantum BioPharma retains a 19.84% ownership stake in UWI as of March 31, 2026, and is entitled to royalty payments: 7% of sales until cumulative payments reach $250 million, after which the royalty drops to 3% in perpetuity. The company also retains 100% of rights to develop similar products for pharmaceutical and medical uses.
The dual approach reflects a broader industry trend where biotech firms seek near-term revenue through commercial products to fund longer-term drug development pipelines. For Quantum BioPharma, the unbuzzd revenue stream could provide critical non-dilutive funding for Lucid-MS and other pipeline candidates. The company’s focus on neurodegenerative and metabolic disorders, as well as alcohol misuse, positions it in high-need therapeutic areas.
Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, a condition that affects the central nervous system and can lead to severe disability. The upcoming Phase 2 trial represents a significant milestone, as it will test the drug in humans for the first time. Success could open a substantial market, given the limited treatment options for MS-related mobility impairment.
Quantum BioPharma’s broader portfolio includes drug candidates in various stages of development for challenging conditions. The company is dedicated to building innovative assets and biotech solutions, as detailed on its newsroom. The BioMedWire podcast appearance provided a platform to articulate the company’s vision and progress, with Durkacz emphasizing the potential of both Lucid-MS and unbuzzd to address unmet medical needs.
Investors and industry observers will likely watch the Phase 2 trial results closely, as they will provide key data on Lucid-MS’s safety and efficacy. Meanwhile, unbuzzd’s commercial performance will be a tangible indicator of Quantum BioPharma’s ability to execute in the consumer health market. The company’s strategy of leveraging commercial revenues to support clinical development could serve as a model for other small-cap biopharmaceutical firms.
